Abstract
Modern analytical techniques provide an unprecedented insight to biomedical samples, allowing an in depth characterization of cells or body fluids, to the level of genes, transcripts, peptides, proteins, metabolites, or metallic ions. The fine grained picture provided by such approaches holds the promise for a better understanding of complex pathologies, and consequently the personalization of diagnosis, prognosis and treatment procedures. In practice however, technical limitations restrict the resolution of the acquired data, and thus of downstream biomedical inference. As a result, the study of complex diseases like leukemia and other types of cancer is impaired by the high heterogeneity of pathologies as well as patient profiles. In this review, we propose an introduction to the general approach of characterizing samples and inferring biomedical results. We highlight the main limitations of the technique with regards to complex and heterogeneous pathologies, and provide ways to overcome these by improving the ability of experiments in discriminating samples.
Keywords: Omics, systems biology, personalized medicine, high resolution medicine, biomedical data interpretation.
Current Pharmaceutical Biotechnology
Title:Practical Considerations for Omics Experiments in Biomedical Sciences
Volume: 17 Issue: 1
Author(s): Marc Vaudel, Harald Barsnes, Rolf Bjerkvig, Andreas Bikfalvi, Frode Selheim, Frode S Berven and Thomas Daubon
Affiliation:
Keywords: Omics, systems biology, personalized medicine, high resolution medicine, biomedical data interpretation.
Abstract: Modern analytical techniques provide an unprecedented insight to biomedical samples, allowing an in depth characterization of cells or body fluids, to the level of genes, transcripts, peptides, proteins, metabolites, or metallic ions. The fine grained picture provided by such approaches holds the promise for a better understanding of complex pathologies, and consequently the personalization of diagnosis, prognosis and treatment procedures. In practice however, technical limitations restrict the resolution of the acquired data, and thus of downstream biomedical inference. As a result, the study of complex diseases like leukemia and other types of cancer is impaired by the high heterogeneity of pathologies as well as patient profiles. In this review, we propose an introduction to the general approach of characterizing samples and inferring biomedical results. We highlight the main limitations of the technique with regards to complex and heterogeneous pathologies, and provide ways to overcome these by improving the ability of experiments in discriminating samples.
Export Options
About this article
Cite this article as:
Vaudel Marc, Barsnes Harald, Bjerkvig Rolf, Bikfalvi Andreas, Selheim Frode, Berven S Frode and Daubon Thomas, Practical Considerations for Omics Experiments in Biomedical Sciences, Current Pharmaceutical Biotechnology 2016; 17 (1) . https://dx.doi.org/10.2174/1389201016666150817095348
DOI https://dx.doi.org/10.2174/1389201016666150817095348 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Pathways Involved in the Early and Late Damage Induced by Testis Ischemia: Evidence for a Rational Pharmacological Modulation
Current Medicinal Chemistry Visceral Adiposity Measurements, Metabolic and Inflammatory Profi le in Obese Patients with and Without Type 2 Diabetes Mellitus: A Crosssectional Analysis
Current Diabetes Reviews Fragile X Syndrome and Alzheimers Disease: Another Story About APP and β -Amyloid
Current Alzheimer Research Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins
Current Pharmaceutical Design Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Modified Release Biodegradable Polymeric Microspheres of Stavudine: Cell Viability, Cellular Uptake, Hemolysis Studies and In Vivo Pharmacokinetics
Current HIV Research Pharmaceutical Strategies for Activating Sirtuins
Current Pharmaceutical Design Characterization of Bovine Tau-Preparations by Two-Dimensional Gel Electrophoresis
Protein & Peptide Letters Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Current Medicinal Chemistry Non-Nucleoside HIV-1 Reverse Transcriptase (RT) Inhibitors: Past, Present, and Future Perspectives
Current Pharmaceutical Design Von Willebrand Factor: Drug and Drug Target
Cardiovascular & Hematological Disorders-Drug Targets Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Modern Pathology: Protein Mis-Folding and Mis-Processing in Complex Disease
Current Protein & Peptide Science Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Current Vascular Pharmacology AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models
Current Alzheimer Research